Drug intelligence / Profile preview

VT-Tri(1)-A

Development stage: Unknown
Lead developer: ViGenCell
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

VT-Tri(1)-A is a recombinant protein-based vaccine candidate developed by VaxThera for the prevention of COVID-19. It is designed as a "triple-antigen" vaccine, incorporating multiple components of the SARS-CoV-2 virus to elicit a broad immune response. The vaccine is produced using a recombinant protein platform, which is intended to be scalable and stable for distribution in regions like Latin America. VaxThera, a Colombian biotechnology company backed by Seguros Sura, initiated clinical development to provide regional vaccine manufacturing autonomy. The vaccine is administered via intramuscular injection and has been evaluated in Phase 1/2 clinical trials in Colombia.

Other names: VaxThera COVID-19 vaccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on VT-Tri(1)-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VT-Tri(1)-A.

Explore the full profile